Arzhang Cyrus Javan

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.688Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad287

Top 29%

0.688DataRank

Top 29%7 citations

Kara W Chew, Joseph J. Eron, Jonathan Z. Li, Mauricio Pinilla, Carlee Moser +32 more

Papers

Driven by 40 papers — median percentile 35. Top paper: “Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection”.

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

Annals of Internal Medicine(2023)10.7326/m22-2381

N/A

2.0DataRank · unranked

63 citations

Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl +41 more

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

Nature Microbiology(2022)10.1038/s41564-022-01254-1

N/A

1.6DataRank · unranked

53 citations

Kara W Chew, Rinki Deo, James P. Flynn, James Regan, Charles R. Crain +51 more

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection

Clinical Pharmacology & Therapeutics(2022)10.1002/cpt.2706

N/A

1.2DataRank · unranked

14 citations

David A. Wohl, Rosalin Arends, Venkatesh Pilla Reddy, Ying Mu, Arzhang Cyrus Javan +8 more

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

Annals of Internal Medicine(2023)10.7326/m22-3428

N/A

0.785DataRank · unranked

31 citations

Kara W Chew, Mark J Giganti, Carlee Moser, Mauricio Pinilla, David A. Wohl +76 more

Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad287

Top 29%

0.688DataRank

Top 29%7 citations

Kara W Chew, Joseph J. Eron, Jonathan Z. Li, Mauricio Pinilla, Carlee Moser +32 more

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

medRxiv(2021)10.1101/2021.12.17.21268009

N/A

0.626DataRank · unranked

14 citations

Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert W. Coombs +18 more

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial

Clinical Infectious Diseases(2023)10.1093/cid/ciad342

N/A

0.622DataRank · unranked

19 citations

Kara W Chew, Mark J Giganti, Eric S. Daar, David A. Wohl, Arzhang Cyrus Javan +47 more

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102250

N/A

0.587DataRank · unranked

12 citations

Kara W Chew, Mark J Giganti, Michael D. Hughes, Carlee Moser, Mark Main +79 more

Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019

Clinical Infectious Diseases(2022)10.1093/cid/ciac818

N/A

0.583DataRank · unranked

10 citations

Linda J Harrison, Kara W Chew, Judy Currier, David A. Wohl, Eric S. Daar +12 more

Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad013

N/A

0.496DataRank · unranked

12 citations

Kara W Chew, Carlee Moser, David A. Wohl, Eric S. Daar, Jonathan Z. Li +42 more

Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.10039

N/A

0.490DataRank · unranked

11 citations

Kara W Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan +47 more

Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials

(2023)10.1093/infdis/jiad285

N/A

0.475DataRank · unranked

7 citations

Kara W Chew, Mark J Giganti, Jonathan Z. Li, Evgenia Aga, Justin Ritz +24 more

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad246

N/A

0.463DataRank · unranked

15 citations

Carlee Moser, Joseph J. Eron, Kara W Chew, Davey M. Smith, Arzhang Cyrus Javan +13 more

Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad209

N/A

0.344DataRank · unranked

8 citations

Kara W Chew, Justin Ritz, Matthew Newell, Arzhang Cyrus Javan, Joseph J. Eron +19 more

Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad300

N/A

0.270DataRank · unranked

3 citations

Carlee Moser, Eunice Yeh, David A. Wohl, Eric S. Daar, Justin Ritz +7 more

Long COVID After Bamlanivimab Treatment

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad286

N/A

0.251DataRank · unranked

4 citations

Carlee Moser, Nikolaus Jilg, Eunice Yeh, Busola Sanusi, David A. Wohl +32 more

Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae369

N/A

0.165DataRank · unranked

2 citations

Babafemi Taiwo, Carlee Moser, Eric S. Daar, David A. Wohl, Justin Ritz +46 more

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

Open Forum Infectious Diseases(2025)10.1093/ofid/ofaf542

N/A

0DataRank · unranked

1 citations

Manish C. Choudhary, Owen T. Glover, Rachel Bender Ignacio, Julie Boucau, Kara W Chew +21 more

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

iScience(2025)10.1016/j.isci.2025.111938

N/A

0DataRank · unranked

1 citations

Kara W Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan +14 more

Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19

UNC Libraries(2025)10.17615/jgjx-bf38

Top 100%

0DataRank

Top 100%0 citations

ACTIV- A Study Team, William A. Fischer, Jonathan Z. Li, Kara W Chew, Arzhang Cyrus Javan +12 more

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial

UNC Libraries(2025)10.17615/zdax-rk30

N/A

0DataRank · unranked

0 citations

Atasi Jana, Eric S. Daar, Arzhang Cyrus Javan, Carlee Moser, Judith S. Currier +16 more

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

UNC Libraries(2025)10.17615/ryrv-wq75

N/A

0DataRank · unranked

0 citations

Yan Li, Jonathan Z. Li, Rachel Bender Ignacio, Kara W Chew, Bharat Mocherla +23 more

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy

medRxiv(2021)10.1101/2021.09.03.21263105

N/A

0DataRank · unranked

21 citations

Kara W Chew, Rinki Deo, James P. Flynn, James Regan, Charles R. Crain +23 more

Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial

UNC Libraries(2025)10.17615/h4dx-ze98

N/A

0DataRank · unranked

0 citations

Luke, Thomas, David A. Wohl, Alexander L. Greninger, Christoph Bausch, Davey M. Smith +16 more

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

medRxiv(2021)10.1101/2021.12.25.21268211

N/A

0DataRank · unranked

6 citations

Kara W Chew, Manish C. Choudhary, Rinki Deo, James Regan, James P. Flynn +20 more

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Nature Communications(2022)10.1038/s41467-022-32551-2

N/A

0DataRank · unranked

49 citations

Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert W. Coombs +21 more

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19

Open Forum Infectious Diseases(2022)10.1093/ofid/ofac618

N/A

0DataRank · unranked

14 citations

Jonathan Z. Li, Joseph J. Eron, Evgenia Aga, Eric S. Daar, David A. Wohl +29 more

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Cell Reports Medicine(2022)10.1016/j.xcrm.2022.100678

N/A

0DataRank · unranked

20 citations

Kara W Chew, Manish C. Choudhary, Rinki Deo, James Regan, James P. Flynn +19 more

Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials

medRxiv(2023)10.1101/2023.03.13.23287208

N/A

0DataRank · unranked

2 citations

Kara W Chew, Mark J Giganti, Jonathan Z. Li, Evgenia Aga, Justin Ritz +10 more

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19

UNC Libraries(2023)10.17615/vptt-dg28

N/A

0DataRank · unranked

0 citations

Arzhang Cyrus Javan, Joseph J. Eron, Justin Ritz, Judith S. Currier, Prasanna Jagannathan +12 more

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

UNC Libraries(2023)10.17615/s90c-rs31

N/A

0DataRank · unranked

0 citations

Jonathan Z. Li, Paul Klekotka, James P. Flynn, Joseph J. Eron, Justin Ritz +23 more

Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019

UNC Libraries(2023)10.17615/x7r0-1v04

N/A

0DataRank · unranked

0 citations

Joseph J. Eron, Kara W Chew, Michael D. Hughes, Carlee Moser, Judy Currier +12 more

Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19

UNC Libraries(2023)10.17615/ra63-p116

N/A

0DataRank · unranked

0 citations

Jonathan Z. Li, Carlee Moser, Arzhang Cyrus Javan, Judy Currier, Michael D. Hughes +12 more

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102787

N/A

0DataRank · unranked

3 citations

Carlee Moser, Nikolaus Jilg, Justin Ritz, David A. Wohl, Jonathan Z. Li +89 more

ACTIV trials: cross-trial lessons learned for master protocol implementation

Journal of Clinical and Translational Science(2024)10.1017/cts.2024.507

N/A

0DataRank · unranked

3 citations

Stacey J. Adam, Indira Brar, Lucy Chung, Judith S. Currier, Eric S. Daar +16 more

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.

Pathogens and Immunity(2024)10.20411/pai.v9i1.660

N/A

0DataRank · unranked

0 citations

Kara W Chew, Mark J Giganti, Ying Mu, Courtney V. Fletcher, Judith S. Currier +12 more

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

UNC Libraries(2024)10.17615/14jx-sy24

N/A

0DataRank · unranked

0 citations

Carlee Moser, Mark J Giganti, Joseph J. Eron, Katya Corado, ACTIV- A Study Team +13 more

Viral and Symptom Rebound Following Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae501

N/A

0DataRank · unranked

0 citations

Brooke McGinley, Carlee Moser, Jonathan Z. Li, Teresa H. Evering, Justin Ritz +42 more

Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities

Biotechnology Advances(2025)10.1016/j.biotechadv.2025.108592

N/A

0DataRank · unranked

9 citations

Revanth Reddy, Arzhang Cyrus Javan, Behnam Hajihossainlou, Ralph Weissleder, Anthony Guiseppi‐Elie +4 more

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.107887

N/A

0DataRank · unranked

1 citations

Kara W Chew, Carlee Moser, Joseph J. Eron, Mauricio Pinilla, Jonathan Z. Li +8 more

Arzhang Cyrus Javan

Indexed papers

Top data-sharing exemplar

Papers